Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gastrointestinal stromal tumors: who should get imatinib and for how long?

Advances in surgery - 1 Jan 2014

Balachandran Vinod P, DeMatteo Ronald P

Abstract excerpt

The application of imatinib for the treatment of GIST remains a remarkable illustration of the ability and promise of targeted molecular therapy. It is gradually becoming evident that the benefit of imatinib depends on the complex interplay between mutational variations that govern tumor sensitivity to the drug, and biological variables that drive clinical outcome. Evidence is mounting that only a select fraction...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Chemotherapy, Adjuvant
Share to Gastrointestinal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Receptor, Platelet-Derived Growth Factor alpha

Source

Open in PubMed Open full text

Identifiers

PMID: 25293614
DOI: 10.1016/j.yasu.2014.05.014
PMCID: PMC4191869

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gastrointestinal stromal tumors: who should get imatinib and for how long?PMID 25293614Read ↗

Targeted therapy and personalized medicine in gastrointestinal stromal tumors: drug resistance, mechanisms, and treatment strategiesSemantic proximity Read ↗

Targeted Therapy for Advanced Gastrointestinal Stromal Tumors: Evolution and Future Directions.Semantic proximity Read ↗

Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

Gastrointestinal stromal tumours: origin and molecular oncology.Semantic proximity Read ↗

Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor.Semantic proximity Read ↗

Imatinib treatment for gastrointestinal stromal tumour (GIST).Semantic proximity Read ↗

Imatinib mesilate for the treatment of gastrointestinal stromal tumour.Semantic proximity Read ↗

Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?Semantic proximity Read ↗

Gastrointestinal Stromal Tumor: Current Approaches and Future Directions in the Treatment of Advanced Disease.Semantic proximity Read ↗

Gastrointestinal stromal tumor: a bridge between bench and bedside.Semantic proximity Read ↗

Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA AnalysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.